DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $359 | -37.5% | 17,381 | -30.2% | 0.00% | -40.0% |
| Q1 2023 | $574 | -99.9% | 24,907 | +6.3% | 0.01% | -44.4% |
| Q3 2022 | $719,000 | -61.9% | 23,434 | -63.5% | 0.01% | -60.9% |
| Q2 2022 | $1,889,000 | +14.9% | 64,187 | +206.3% | 0.02% | +27.8% |
| Q2 2021 | $1,644,000 | +702.0% | 20,959 | +266.2% | 0.02% | +350.0% |
| Q3 2020 | $205,000 | -45.8% | 5,723 | -63.4% | 0.00% | -60.0% |
| Q2 2020 | $378,000 | +147.1% | 15,637 | +56.4% | 0.01% | +100.0% |
| Q3 2019 | $153,000 | -52.2% | 10,000 | -27.4% | 0.01% | -79.2% |
| Q1 2019 | $320,000 | – | 13,770 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |